



(51) International Patent Classification:
C07K 14/55 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2024/037942

(22) International Filing Date:
12 July 2024 (12.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/513,540 13 July 2023 (13.07.2023) US

(71) Applicant: **OUTPACE BIO, INC.** [US/US]; 700 Dexter Ave N., Suite 300, Seattle, Washington 98109 (US).

(72) Inventors: **BOYKEN, Scott**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US). **LAJOIE, Marc**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US). **DAVENPORT, Thaddeus M.**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US). **MOFFETT, Howell**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US). **WEITZNER, Brian**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US). **NG, Andrew Howen**; 700 Dexter Avenue N., Suite 300,

Seattle, Washington 98109 (US). **SAMPLE, Paul Joseph**; 700 Dexter Avenue N., Suite 300, Seattle, Washington 98109 (US).

(74) Agent: **HAN, Eunhee** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: DESIGNED INTERLEUKIN-2 CYTOKINE COMPOSITIONS AND METHODS FOR USE




FIG. 1A

(57) Abstract: The disclosure provides a polypeptide comprising (a) a sequence comprising alpha helices H1, H2, H3 and H4, wherein, from an amino terminus to a carboxy terminus, a first loop (L1) connects H1 and H4, a second loop (L2) connects H4 and H2, a third loop (L3) connects H2 and H3, wherein the polypeptide binds to an IL-2 receptor beta-gamma (IL- 2Rβγ); and (b) a targeting moiety that binds to a sequence of a cluster of differentiation 8 (CD8) glycoprotein.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*